Y Hirsch-Moverman1, J Bethel, P W Colson, J Franks, W El-Sadr. 1. Charles P Felton National Tuberculosis Center, International Center for AIDS Care and Treatment Programs, Mailman School of Public Health, Columbia University, New York, New York 10027, USA. yh154@columbia.edu
Abstract
BACKGROUND: Few studies have examined predictors of latent tuberculosis infection (LTBI) treatment completion in inner city populations in the United States. OBJECTIVE: To assess LTBI treatment completion rates and predictors in an inner city cohort. METHODS: Data from control groups of two sequentially conducted randomized controlled trials of LTBI treatment were analyzed for treatment completion rates. Participants in Study A (n = 191), conducted in 1996-1999, self administered daily isoniazid (INH) for 6-12 months, while participants in Study B (n = 123), conducted in 2002-2005, self administered daily INH for 9 months. RESULTS: Overall, 44.6% of participants completed therapy, with significantly higher completion rates in Study B than Study A (37.0% vs. 56.1%, P = 0.001). Marriage and alcohol use were significant predictors of completion (aOR = 2.153, 95%CI 1.301-3.562) and non-completion (aOR = 0.530, 95%CI 0.320-0.877), respectively; multivariate analysis indicated increased completion among married persons of foreign birth and among alcohol users who were homeless. Knowledge of and attitudes to tuberculosis were not significant predictors. CONCLUSIONS: The design provided an opportunity to assess predictors of LTBI treatment completion in this inner city population. Social circumstances were the strongest predictors of treatment completion, suggesting that tangible social services may be more effective than educational programs in encouraging treatment completion.
BACKGROUND: Few studies have examined predictors of latent tuberculosis infection (LTBI) treatment completion in inner city populations in the United States. OBJECTIVE: To assess LTBI treatment completion rates and predictors in an inner city cohort. METHODS: Data from control groups of two sequentially conducted randomized controlled trials of LTBI treatment were analyzed for treatment completion rates. Participants in Study A (n = 191), conducted in 1996-1999, self administered daily isoniazid (INH) for 6-12 months, while participants in Study B (n = 123), conducted in 2002-2005, self administered daily INH for 9 months. RESULTS: Overall, 44.6% of participants completed therapy, with significantly higher completion rates in Study B than Study A (37.0% vs. 56.1%, P = 0.001). Marriage and alcohol use were significant predictors of completion (aOR = 2.153, 95%CI 1.301-3.562) and non-completion (aOR = 0.530, 95%CI 0.320-0.877), respectively; multivariate analysis indicated increased completion among married persons of foreign birth and among alcohol users who were homeless. Knowledge of and attitudes to tuberculosis were not significant predictors. CONCLUSIONS: The design provided an opportunity to assess predictors of LTBI treatment completion in this inner city population. Social circumstances were the strongest predictors of treatment completion, suggesting that tangible social services may be more effective than educational programs in encouraging treatment completion.
Authors: Fred K Shieh; Graham Snyder; C Robert Horsburgh; John Bernardo; Claire Murphy; Jussi J Saukkonen Journal: Am J Respir Crit Care Med Date: 2006-06-29 Impact factor: 21.405
Authors: Armen E Parsyan; Jussi Saukkonen; M Anita Barry; Sharon Sharnprapai; C Robert Horsburgh Journal: J Infect Date: 2006-06-12 Impact factor: 6.072
Authors: Diane E Bennett; Jeanne M Courval; Ida Onorato; Tracy Agerton; Judy D Gibson; Lauren Lambert; Geraldine M McQuillan; Brenda Lewis; Thomas R Navin; Kenneth G Castro Journal: Am J Respir Crit Care Med Date: 2007-11-07 Impact factor: 21.405
Authors: U Mack; G B Migliori; M Sester; H L Rieder; S Ehlers; D Goletti; A Bossink; K Magdorf; C Hölscher; B Kampmann; S M Arend; A Detjen; G Bothamley; J P Zellweger; H Milburn; R Diel; P Ravn; F Cobelens; P J Cardona; B Kan; I Solovic; R Duarte; D M Cirillo Journal: Eur Respir J Date: 2009-05 Impact factor: 16.671
Authors: C Robert Horsburgh; Stefan Goldberg; James Bethel; Shande Chen; Paul W Colson; Yael Hirsch-Moverman; Stephen Hughes; Robin Shrestha-Kuwahara; Timothy R Sterling; Kirsten Wall; Paul Weinfurter Journal: Chest Date: 2009-09-30 Impact factor: 9.410
Authors: Jamie P Morano; Alexei Zelenev; Mary R Walton; R Douglas Bruce; Frederick L Altice Journal: Am J Public Health Date: 2014-06-12 Impact factor: 9.308
Authors: F K Mukinda; D Theron; G D van der Spuy; K R Jacobson; M Roscher; E M Streicher; A Musekiwa; G J Coetzee; T C Victor; B J Marais; J B Nachega; R M Warren; H S Schaaf Journal: Int J Tuberc Lung Dis Date: 2012-02 Impact factor: 2.373
Authors: Sara Lodi; Nneka I Emenyonu; Kara Marson; Dalsone Kwarisiima; Robin Fatch; Michael G McDonell; Debbie M Cheng; Harsha Thirumurthy; Monica Gandhi; Carol S Camlin; Winnie R Muyindike; Judith A Hahn; Gabriel Chamie Journal: Trials Date: 2021-05-20 Impact factor: 2.279
Authors: Tom Wingfield; Marco A Tovar; Doug Huff; Delia Boccia; Matthew J Saunders; Sumona Datta; Rosario Montoya; Eric Ramos; James J Lewis; Robert H Gilman; Carlton Evans Journal: Clin Med (Lond) Date: 2016-12 Impact factor: 2.659